Accepted for Publication: May 11, 2020.
Published: June 5, 2020. doi:10.1001/jamanetworkopen.2020.11192
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Mortus JR et al. JAMA Network Open.
Corresponding Author: Todd K. Rosengart, MD, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, MS: BCM 390, Houston, TX 77030 (firstname.lastname@example.org).
Author Contributions: Drs Mortus and Rosengart had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Mortus, Manek, Loor, Cruz, Trautner, Rosengart.
Acquisition, analysis, or interpretation of data: Mortus, Manek, Brubaker, Rosengart.
Drafting of the manuscript: Mortus, Manek, Brubaker, Cruz, Rosengart.
Critical revision of the manuscript for important intellectual content: Mortus, Manek, Brubaker, Loor, Trautner, Rosengart.
Statistical analysis: Mortus.
Administrative, technical, or material support: Brubaker, Loor, Trautner.
Conflicts of Interest Disclosures: Dr Cruz reported being the founder of A2 Therapeutics and owning patent No. 7879793. Dr Trautner reported receiving grants from the Agency for Healthcare Research and Quality, Department of Veterans Affairs (VA) Health Services Research and Development Service, Rehabilitation Research and Development, and Zambon Pharmaceuticals and personal fees from Paratek outside the submitted work. No other disclosures were reported.
Funding/Support: Dr Brubaker is supported by grant No. T32 HL139425 from the National Institutes of Health and National Heart, Lung, and Blood Institute. Dr Trautner is supported in part by grant No. 13-413 from the Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, Texas. Dr Cruz is supported in part by the Merit Review Award I01 BX002551 from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the US government.
Additional Contributions: Wei Qi, MS, provided statistical analysis for this study. Miriam King, MEd, assisted with manuscript preparation. Robert Southard, MD, and Yesenia Rojas-Khalil, MD (Baylor St Luke Medical Center); and Laila Eugenia Woc-Colburn, MD, and Meredith Reyes, MD (Baylor College of Medicine) assisted in developing material related to this study. They were not compensated for their contributions.
H , Yang
L , Liu
et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med
. Published online March 16, 2020;/j/cclm.ahead-of-print/cclm-2020-0188/cclm-2020-0188.xml. doi:10.1515/cclm-2020-0188PubMedGoogle Scholar
N , Bai
H , Chen
X , Gong
J , Li
D , Sun
Z . Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost
. 2020;18(5):1094-1099. doi:10.1111/jth.14817PubMedGoogle ScholarCrossref
M , Duarte-Neto
AN , de Almeida Monteiro
et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost
. Published online April 15, 2020. doi:10.1111/jth.14844PubMedGoogle Scholar